January 2022

Pharmacovigilance of a single drug is one thing, but when it comes to polypharmacy – taking multiple medications at once – getting to the bottom of an adverse event is even more complex. Which drug of several caused the adverse event, or did interactions between them play a role?

In the next issue of Pharma Technology Focus, we explore the challenges of safety reporting in patients taking more than one drug, and how the process – and patient safety – can be improved.

Elsewhere, we speak to XIL Health founder and CEO Susan Lang to find out if 3D printed drugs can live up to the hype as the future of pharma, revolutionising personalised medicine, impacting drug distribution and tackling infectious diseases and sustainability.

All this plus the latest trends and innovations in the pharma industry, as well as up-to-date analysis and insight from GlobalData experts.


Editor | Eloise McLennan

Writers | Abi Millar, Darcy Jimenez, Giacomo Lee, William Newton, John Price
Magazine Designer | Maria Gimenez

Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Filipe Costa, Martina Labaiova, Dimeji Akinkuolie, Will Ingham
Lead Designer | John Hammond 

Publisher | Susanne Hauner
Digital Publishing Director | Duncan West


Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2021 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.